$18.18
0.38% yesterday
Nasdaq, Nov 25, 10:04 pm CET
ISIN
US89422G1076
Symbol
TVTX
Sector
Industry

Travere Therapeutics Inc Stock price

$18.18
+0.65 3.71% 1M
+12.02 195.13% 6M
+9.19 102.22% YTD
+12.29 208.66% 1Y
-12.12 40.00% 3Y
+4.08 28.94% 5Y
+9.20 102.45% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.07 0.38%
ISIN
US89422G1076
Symbol
TVTX
Sector
Industry

Key metrics

Market capitalization $1.58b
Enterprise Value $1.71b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8.39
P/S ratio (TTM) P/S ratio 7.78
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -2.96%
Revenue (TTM) Revenue $203.45m
EBIT (operating result TTM) EBIT $-279.69m
Free Cash Flow (TTM) Free Cash Flow $-272.34m
Cash position $277.44m
EPS (TTM) EPS $-4.56
P/E forward negative
P/S forward 6.90
EV/Sales forward 7.45
Short interest 11.49%
Show more

Is Travere Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Travere Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Travere Therapeutics Inc forecast:

14x Buy
88%
2x Hold
13%

Analyst Opinions

16 Analysts have issued a Travere Therapeutics Inc forecast:

Buy
88%
Hold
13%

Financial data from Travere Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
203 203
3% 3%
100%
- Direct Costs 53 53
2% 2%
26%
150 150
3% 3%
74%
- Selling and Administrative Expenses 173 173
13% 13%
85%
- Research and Development Expense 214 214
11% 11%
105%
-236 -236
17% 17%
-116%
- Depreciation and Amortization 43 43
2% 2%
21%
EBIT (Operating Income) EBIT -280 -280
15% 15%
-137%
Net Profit -352 -352
12% 12%
-173%

In millions USD.

Don't miss a Thing! We will send you all news about Travere Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Travere Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about 15 hours ago
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in December:
Negative
Investors Business Daily
7 days ago
Kidney disease leader Travere Therapeutics is pulling back to a key support level on the stock market today. The post Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level appeared first on Investor's Business Daily.
Neutral
GlobeNewsWire
13 days ago
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 24,400 shares of its common stock. These inducement RSUs are subject to the...
More Travere Therapeutics Inc News

Company Profile

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Head office United States
CEO Eric Dube
Employees 380
Founded 2008
Website www.travere.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today